Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: A need for screening tools to target interventions

Nutrition

Volumn 29, Issue 2, 2013, Pages 379-386

  DeBoer, Mark D ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Adiponectin; Adolescents; High sensitivity C reactive protein; Inflammation; Insulin resistance; Metabolic syndrome; Obesity; Risk

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; INSULIN; RETINOL BINDING PROTEIN 4;

ADOLESCENT; ARTERIAL WALL THICKENING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CLINICAL EXAMINATION; CYTOKINE RELEASE; DIABETES MELLITUS; DISEASE COURSE; FAMILY HISTORY; HIGH RISK POPULATION; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LABORATORY TEST; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MOTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCREENING TEST;

ADIPONECTIN; ADOLESCENT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIFE STYLE; METABOLIC SYNDROME X; OBESITY; RISK ASSESSMENT; RISK FACTORS;

EID: 84872271216     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2012.07.003     Document Type: Review

References (85)

1. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report. Pediatrics 2011, 128(suppl 5):S1-44.
2. Wilson P.W., D'Agostino R.B., Sullivan L., Parise H., Kannel W.B. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002, 162:1867-1872.
3. Juonala M., Magnussen C.G., Berenson G.S., Venn A., Burns T.L., Sabin M.A., et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med 2011, 365:1876-1885.
4. Wildman R.P., Muntner P., Reynolds K., McGinn A.P., Rajpathak S., Wylie-Rosett J., et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008, 168:1617-1624.
5. Morrison J.A., Glueck C.J., Daniels S., Wang P., Stroop D. Paradoxically high adiponectin in obese 16-year-old girls protects against appearance of the metabolic syndrome and its components seven years later. J Pediatr 2011, 158:208-214.
6. Savoye M., Nowicka P., Shaw M., Yu S., Dziura J., Chavent G., et al. Long-term results of an obesity program in an ethnically diverse pediatric population. Pediatrics 2011, 127:402-410.
7. Wickham E.P., Stern M., Evans R.K., Bryan D.L., Moskowitz W.B., Clore J.N., et al. Prevalence of the metabolic syndrome among obese adolescents enrolled in a multidisciplinary weight management program: clinical correlates and response to treatment. Metab Syndr Relat Disord 2009, 7:179-186.
8. Walker S.E., Smolkin M.E., O'Leary L.L., Cluett S.B., Norwood V.F., DeBoer M.D., et al. Predictors of retention and BMI loss or stabilization in obese youth enrolled in a weight loss intervention. Obes Res Clin Pract 2011, Available at:. http://www.sciencedirect.com/science/journal/1871403X.
9. Ford E.S., Li C., Cook S., Choi H.K. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007, 115:2526-2532.
10. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
11. Zimmet P., Alberti G., Kaufman F., Tajima N., Silink M., Arslanian S., et al. The metabolic syndrome in children and adolescents. Lancet 2007, 369:2059-2061.
12. Morrison J.A., Friedman L.A., Wang P., Glueck C.J. Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later. J Pediatr 2008, 152:201-206.
13. DeBoer M.D., Gurka M.J. Ability among adolescents for the metabolic syndrome to predict elevations in factors associated with type 2 diabetes and cardiovascular disease: data from the National Health and Nutrition Examination Survey 1999-2006. Metab Syndr Relat Disord 2010, 8:343-353.
14. DeBoer M.D. Ethnicity, obesity and the metabolic syndrome: implications on assessing risk and targeting intervention. Expert Rev Endocrinol Metab 2011, 6:279-289.
15. Barzilay J.I., Abraham L., Heckbert S.R., Cushman M., Kuller L.H., Resnick H.E., et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001, 50:2384-2389.
16. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
17. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000, 321:199-204.
18. Freeman D.J., Norrie J., Caslake M.J., Gaw A., Ford I., Lowe G.D., et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002, 51:1596-1600.
19. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
20. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
21. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
22. de Ferranti S., Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem 2008, 54:945-955.
23. Tilg H., Moschen A.R. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008, 14:222-231.
24. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
25. Lee S., Bacha F., Gungor N., Arslanian S.A. Racial differences in adiponectin in youth: relationship to visceral fat and insulin sensitivity. Diabetes Care 2006, 29:51-56.
26. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
27. Abel E.D., Peroni O., Kim J.K., Kim Y.B., Boss O., Hadro E., et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001, 409:729-733.
28. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
29. Graham T.E., Yang Q., Bluher M., Hammarstedt A., Ciaraldi T.P., Henry R.R., et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006, 354:2552-2563.
30. Yao-Borengasser A., Varma V., Bodles A.M., Rasouli N., Phanavanh B., Lee M.J., et al. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab 2007, 92:2590-2597.
31. Calabro P., Chang D.W., Willerson J.T., Yeh E.T. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005, 46:1112-1113.
32. Stein M.P., Edberg J.C., Kimberly R.P., Mangan E.K., Bharadwaj D., Mold C., et al. C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest 2000, 105:369-376.
33. Ridker P.M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007, 49:2129-2138.
34. Wee C.C., Mukamal K.J., Huang A., Davis R.B., McCarthy E.P., Mittleman M.A. Obesity and C-reactive protein levels among white, black, and Hispanic US adults. Obesity (Silver Spring) 2008, 16:875-880.
35. Danenberg H.D., Szalai A.J., Swaminathan R.V., Peng L., Chen Z., Seifert P., et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003, 108:512-515.
36. Datta S., Iqbal Z., Prasad K.R. Comparison between serum hsCRP and LDL cholesterol for search of a better predictor for ischemic heart disease. Indian J Clin Biochem 2011, 26:210-213.
37. Defronzo R.A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
38. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610-614.
39. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.W., Karin M., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673-1677.
40. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
41. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
42. Wu T., Dorn J.P., Donahue R.P., Sempos C.T., Trevisan M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2002, 155:65-71.
43. Forouhi N.G., Sattar N., McKeigue P.M. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord 2001, 25:1327-1331.
44. Herder C., Schneitler S., Rathmann W., Haastert B., Schneitler H., Winkler H., et al. Low-grade inflammation, obesity, and insulin resistance in adolescents. J Clin Endocrinol Metab 2007, 92:4569-4574.
45. Moran A., Steffen L.M., Jacobs D.R., Steinberger J., Pankow J.S., Hong C.P., et al. Relation of C-reactive protein to insulin resistance and cardiovascular risk factors in youth. Diabetes Care 2005, 28:1763-1768.
46. Shea S., Aymong E., Zybert P., Shamoon H., Tracy R.P., Deckelbaum R.J., et al. Obesity, fasting plasma insulin, and C-reactive protein levels in healthy children. Obes Res 2003, 11:95-103.
47. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 2006, 116:1793-1801.
48. Haffner S., Temprosa M., Crandall J., Fowler S., Goldberg R., Horton E., et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005, 54:1566-1572.
49. Balagopal P., George D., Patton N., Yarandi H., Roberts W.L., Bayne E., et al. Lifestyle-only intervention attenuates the inflammatory state associated with obesity: a randomized controlled study in adolescents. J Pediatr 2005, 146:342-348.
50. Reinehr T., Stoffel-Wagner B., Roth C.L., Andler W. High-sensitive C-reactive protein, tumor necrosis factor alpha, and cardiovascular risk factors before and after weight loss in obese children. Metabolism 2005, 54:1155-1161.
51. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
52. Mizuno Y., Jacob R.F., Mason R.P. Inflammation and the development of atherosclerosis. J Atheroscler Thromb 2011, 18:351-358.
53. Halim S.A., Newby L.K., Ohman E.M. Biomarkers in cardiovascular clinical trials: past, present, future. Clin Chem 2012, 58:45-53.
54. Boyle A.J., Yeghiazarians Y., Shih H., Hwang J., Ye J., Sievers R., et al. Myocardial production and release of MCP-1 and SDF-1 following myocardial infarction: differences between mice and man. J Transl Med 2010, 9:150.
55. Farouk S.S., Rader D.J., Reilly M.P., Mehta N.N. CXCL12: a new player in coronary disease identified through human genetics. Trends Cardiovasc Med 2010, 20:204-209.
56. Berenson G.S., Srinivasan S.R., Bao W., Newman W.P., Tracy R.E., Wattigney W.A. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998, 338:1650-1656.
57. de Maat M.P., Trion A. C-reactive protein as a risk factor versus risk marker. Curr Opin Lipidol 2004, 15:651-657.
58. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
59. Sinaiko A.R., Steinberger J., Moran A., Prineas R.J., Vessby B., Basu S., et al. Relation of body mass index and insulin resistance to cardiovascular risk factors, inflammatory factors, and oxidative stress during adolescence. Circulation 2005, 111:1985-1991.
60. DeBoer M.D., Gurka M.J., Sumner A.E. Diagnosis of the metabolic syndrome is associated with disproportionately high levels of high-sensitivity C-reactive protein in non-Hispanic black adolescents: an analysis of NHANES 1999-2008. Diabetes Care 2011, 34:734-740.
61. Oliveira A.C., Oliveira A.M., Adan L.F., Oliveira N.F., Silva A.M., Ladeia A.M. C-reactive protein and metabolic syndrome in youth: a strong relationship?. Obesity (Silver Spring) 2008, 16:1094-1098.
62. Retnakaran R., Hanley A.J., Connelly P.W., Harris S.B., Zinman B. Elevated C-reactive protein in Native Canadian children: an ominous early complication of childhood obesity. Diabetes Obes Metab 2006, 8:483-491.
63. Siervo M., Ruggiero D., Sorice R., Nutile T., Aversano M., Iafusco M., et al. Body mass index is directly associated with biomarkers of angiogenesis and inflammation in children and adolescents. Nutrition 2012, 28:262-266.
64. Lambert M., Delvin E.E., Paradis G., O'Loughlin J., Hanley J.A., Levy E. C-reactive protein and features of the metabolic syndrome in a population-based sample of children and adolescents. Clin Chem 2004, 50:1762-1768.
65. Ford E.S., Ajani U.A., Mokdad A.H. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care 2005, 28:878-881.
66. Mattsson N., Ronnemaa T., Juonala M., Viikari J.S., Raitakari O.T. Childhood predictors of the metabolic syndrome in adulthood. The Cardiovascular Risk in Young Finns Study. Ann Med 2008, 40:542-552.
67. Jarvisalo M.J., Harmoinen A., Hakanen M., Paakkunainen U., Viikari J., Hartiala J., et al. Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler Thromb Vasc Biol 2002, 22:1323-1328.
68. Meyer A.A., Kundt G., Steiner M., Schuff-Werner P., Kienast W. Impaired flow-mediated vasodilation, carotid artery intima-media thickening, and elevated endothelial plasma markers in obese children: the impact of cardiovascular risk factors. Pediatrics 2006, 117:1560-1567.
69. Albert M.A., Ridker P.M. C-reactive protein as a risk predictor: do race/ethnicity and gender make a difference?. Circulation 2006, 114:e67-e74.
70. DeBoer M.D., Dong L., Gurka M.J. Racial/Ethnic and sex differences in the ability of metabolic syndrome criteria to predict elevations in fasting insulin levels in adolescents. J Pediatr 2011, 159:975-981.
71. Sumner A.E. Ethnic differences in triglyceride levels and high-density lipoprotein lead to underdiagnosis of the metabolic syndrome in black children and adults. J Pediatr 2009, 155:S7.
72. Renzaho A.M., Halliday J.A., Nowson C. Vitamin D, Obesity, and obesity-related chronic disease among ethnic minorities: a systematic review. Nutrition 2011, 27:868-879.
73. Wing R.R., Phelan S. Long-term weight loss maintenance. Am J Clin Nutr 2005, 82(1 suppl):222S-225S.
74. Chang M.H., Valdez R., Ned R.M., Liu T., Yang Q., Yesupriya A., et al. Influence of familial risk on diabetes risk-reducing behaviors among U.S. adults without diabetes. Diabetes Care 2011, 34:2393-2399.
75. Schwartz B., Jacobs D.R., Moran A., Steinberger J., Hong C.P., Sinaiko A.R. Measurement of insulin sensitivity in children: comparison between the euglycemic-hyperinsulinemic clamp and surrogate measures. Diabetes Care 2008, 31:783-788.
76. Osei K., Rhinesmith S., Gaillard T., Schuster D. Impaired insulin sensitivity, insulin secretion, and glucose effectiveness predict future development of impaired glucose tolerance and type 2 diabetes in pre-diabetic African Americans: implications for primary diabetes prevention. Diabetes Care 2004, 27:1439-1446.
77. Kynde I., Heitmann B.L., Bygbjerg I.C., Andersen L.B., Helge J.W. Hypoadiponectinemia in overweight children contributes to a negative metabolic risk profile 6 years later. Metabolism 2009, 58:1817-1824.
78. McTernan P.G., Kumar S. Editorial: retinol binding protein 4 and pathogenesis of diabetes. J Clin Endocrinol Metab 2007, 92:2430-2432.
79. Friebe D., Neef M., Erbs S., Dittrich K., Kratzsch J., Kovacs P., et al. Retinol binding protein 4 (RBP4) is primarily associated with adipose tissue mass in children. Int J Pediatr Obes 2011, 6:e345-e352.
80. Goodman E., Graham T.E., Dolan L.M., Daniels S.R., Goodman E.R., Kahn B.B. The relationship of retinol binding protein 4 to changes in insulin resistance and cardiometabolic risk in overweight black adolescents. J Pediatr 2009, 154:67-73.
81. DeBoer M.D., Gurka M.J. Low sensitivity for the metabolic syndrome to detect uric acid elevations in females and non-Hispanic-black male adolescents: an analysis of NHANES 1999-2006. Atherosclerosis 2012, 220:575-580.
82. Eisenmann J.C. On the use of a continuous metabolic syndrome score in pediatric research. Cardiovasc Diabetol 2008, 7:17.
83. Kahn R., Buse J., Ferrannini E., Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
84. DeBoer M.D. Underdiagnosis of the metabolic syndrome in non-Hispanic black adolescents: a call for ethnic-specific criteria. Curr Cardiovasc Risk Rep 2010, 4:302-310.
85. Morrison J.A., Glueck C.J., Horn P.S., Wang P. Childhood predictors of adult type 2 diabetes at 9- and 26-year follow-ups. Arch Pediatr Adolesc Med 2010, 164:53-60.